| |
MCI-o
|
Non-AD-D
|
MCI-AD
|
AD-D
|
|---|
|
Number of patients
|
29
|
14
|
13
|
39
|
|
Age, yr
|
69.4 [61–75]
|
65.1 [59–71]
|
73.3 [69–77]
|
72.5 [68–76]a
|
|
Sex, M/F
|
15/14
|
6/8
|
5/8
|
18/21
|
|
MMSE
|
27 [26–28]
|
20 [20–23]b
|
26 [25–28]c
|
21 [19–24]b
|
|
Aβ1-42, pg/ml
|
1262 [1014–1626]
|
1255 [997–1585]
|
638 [590–852]
|
796 [618–928]
|
|
Aβ1-40, pg/ml
|
15,393 [12,208–21,112]
|
13,332 [9303–22,989]
|
21612 [17,875–26,191]
|
20,803 [15,168–24,448]
|
|
t-tau, pg/ml
|
226 [158–246]
|
242 [189–320]
|
580 [487–789]
|
522 [403–708]
|
|
p-tau, pg/ml
|
44 [29–59]
|
46 [41–53]
|
92 [80–113]
|
99 [74–111]
|
-
Aβ β-amyloid, p-tau phosphorylated tau, t-tau total tau, MMSE Mini Mental State Examination, MCI-o mild cognitive impairment not due to Alzheimer’s disease, young control subjects without dementia, non-AD-D dementia not due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease, AD-D Alzheimer’s disease dementia
- The values represent the median [interquartile range]
- Differences between the groups were calculated using a nonparametric Kruskal-Wallis test followed by Dunn’s posttest. No p values were calculated for Aβ, t-tau, and p-tau, as the patients were selected according to these markers
-
a
p < 0.05 vs. non-AD-D
-
b
p < 0.001 vs. MCI-o
-
c
p < 0.01 vs. non-AD-D
